{ "data": { "id": "org_sanofi", "slug": "sanofi", "name": "Sanofi", "short_name": "Sanofi", "type": "company", "tier": 2, "homepage": "https://www.sanofi.com", "country_code": "FR", "reliability_note": null, "url": "https://statorigin.org/sources/sanofi", "documents": [ { "title": "Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines", "url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178", "doc_type": "press_release", "published_date": "2026-09-14", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 4 }, { "title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "doc_type": "press_release", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 36 } ], "statistics": [ { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEV", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEV", "indicator": { "slug": "pharmaceutical-manufacturing-employment", "name": "Pharmaceutical manufacturing employment", "definition": "Total number of personnel employed at a pharmaceutical manufacturing facility." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "HU", "name": "Hungary", "type": "country" }, "period": { "start": "2026-09-14", "end": "2026-09-14", "type": "point" }, "value": 400, "value_text": "c.400", "unit": "count", "currency": null, "scale": "1", "value_type": "estimate", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178", "document_type": "press_release", "locator": "Sanofi and Cheplapharm to create new strategic partnership in mature medicines", "quote": "As part of the project, three manufacturing sites would be transferred to Cheplapharm: Csanyikvölgy in Hungary (c.400 employees), Jurong in Singapore (c.100 employees), and Ploërmel in France (c.65 employees).", "published_date": "2026-09-14", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEV", "bibtex": "@misc{sanofi2026pharmaceuticalbjmgev,\n author = {{Sanofi}},\n title = {Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEV},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEW", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEW", "indicator": { "slug": "pharmaceutical-manufacturing-employment", "name": "Pharmaceutical manufacturing employment", "definition": "Total number of personnel employed at a pharmaceutical manufacturing facility." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "SG", "name": "Singapore", "type": "country" }, "period": { "start": "2026-09-14", "end": "2026-09-14", "type": "point" }, "value": 100, "value_text": "c.100", "unit": "count", "currency": null, "scale": "1", "value_type": "estimate", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178", "document_type": "press_release", "locator": "Sanofi and Cheplapharm to create new strategic partnership in mature medicines", "quote": "As part of the project, three manufacturing sites would be transferred to Cheplapharm: Csanyikvölgy in Hungary (c.400 employees), Jurong in Singapore (c.100 employees), and Ploërmel in France (c.65 employees).", "published_date": "2026-09-14", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEW", "bibtex": "@misc{sanofi2026pharmaceuticalbjmgew,\n author = {{Sanofi}},\n title = {Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEW},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEX", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEX", "indicator": { "slug": "pharmaceutical-manufacturing-employment", "name": "Pharmaceutical manufacturing employment", "definition": "Total number of personnel employed at a pharmaceutical manufacturing facility." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "FR", "name": "France", "type": "country" }, "period": { "start": "2026-09-14", "end": "2026-09-14", "type": "point" }, "value": 65, "value_text": "c.65", "unit": "count", "currency": null, "scale": "1", "value_type": "estimate", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178", "document_type": "press_release", "locator": "Sanofi and Cheplapharm to create new strategic partnership in mature medicines", "quote": "As part of the project, three manufacturing sites would be transferred to Cheplapharm: Csanyikvölgy in Hungary (c.400 employees), Jurong in Singapore (c.100 employees), and Ploërmel in France (c.65 employees).", "published_date": "2026-09-14", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEX", "bibtex": "@misc{sanofi2026pharmaceuticalbjmgex,\n author = {{Sanofi}},\n title = {Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEX},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEY", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEY", "indicator": { "slug": "pharmaceutical-marketing-authorizations", "name": "Pharmaceutical marketing authorizations", "definition": "Total number of active regulatory marketing authorizations held by a pharmaceutical company." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-09-14", "end": "2026-09-14", "type": "point" }, "value": 3440, "value_text": "3,440", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178", "document_type": "press_release", "locator": "About Cheplapharm", "quote": "Driven by a long-term vision of sustainable growth, the Group has invested more than €6.2 billion since its inception, acquired nearly 100 products since 2015, and holds 3,440 marketing authorizations across 160 countries.", "published_date": "2026-09-14", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEY", "bibtex": "@misc{sanofi2026pharmaceuticalbjmgey,\n author = {{Sanofi}},\n title = {Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEY},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_DCHFJWTQKEZNM8SYSXWZT57XQ7", "url": "https://statorigin.org/stat/stat_DCHFJWTQKEZNM8SYSXWZT57XQ7", "indicator": { "slug": "annual-net-sales-growth-guidance-at-constant-exchange-rates", "name": "Annual net sales growth guidance at constant exchange rates", "definition": "Expected percentage increase in full-year net sales at constant exchange rates." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-12-31", "type": "year" }, "value": 10, "value_text": "around 10%", "unit": "percent", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Guidance upgraded", "quote": "In 2026, sales are now expected to grow by around 10% at CER. Business EPS at CER is expected to grow slightly faster than sales.3", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_DCHFJWTQKEZNM8SYSXWZT57XQ7", "bibtex": "@misc{sanofi2026salest57xq7,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_DCHFJWTQKEZNM8SYSXWZT57XQ7},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_SY02QGKVB4X94AC70CRT9QZ2PE", "url": "https://statorigin.org/stat/stat_SY02QGKVB4X94AC70CRT9QZ2PE", "indicator": { "slug": "business-eps-growth-at-constant-exchange-rates", "name": "Business EPS growth at constant exchange rates", "definition": "Percentage growth in non-IFRS business earnings per share calculated at constant exchange rates." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 33.3, "value_text": "33.3%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Business EPS was €2.09, up by 33.3% at CER; 31.4% at actual exchange rates; IFRS EPS €0.29", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_SY02QGKVB4X94AC70CRT9QZ2PE", "bibtex": "@misc{sanofi2026business9qz2pe,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_SY02QGKVB4X94AC70CRT9QZ2PE},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGF8", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF8", "indicator": { "slug": "business-earnings-per-share", "name": "Business earnings per share", "definition": "Adjusted non-IFRS net income per share reflecting ongoing operational business performance." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 2.09, "value_text": "€2.09", "unit": "EUR", "currency": "EUR", "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Q2 sales growth of 17.8% at CER1 and business earnings per share (EPS)2 of €2.09", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF8", "bibtex": "@misc{sanofi2026businessbjmgf8,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF8},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFG", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFG", "indicator": { "slug": "business-earnings-per-share-growth", "name": "Business earnings per share growth", "definition": "Percentage growth in non-IFRS business earnings per share at reported actual exchange rates." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 31.4, "value_text": "31.4%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Business EPS was €2.09, up by 33.3% at CER; 31.4% at actual exchange rates; IFRS EPS €0.29", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFG", "bibtex": "@misc{sanofi2026businessbjmgfg,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFG},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFC", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFC", "indicator": { "slug": "dupixent-sales", "name": "Dupixent sales", "definition": "Total net sales revenue generated by Dupixent (dupilumab)." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 5.2, "value_text": "€5.2 billion", "unit": "EUR", "currency": "EUR", "scale": "billion", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Dupixent sales increased by 37.6% to €5.2 billion, above €5 billion per quarter for the first time", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFC", "bibtex": "@misc{sanofi2026dupixentbjmgfc,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFC},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFK", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFK", "indicator": { "slug": "dupixent-sales-annual", "name": "Dupixent sales (annual)", "definition": "Total net sales revenue generated by Dupixent (dupilumab)." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2030-01-01", "end": "2030-12-31", "type": "year" }, "value": 25, "value_text": "around €25 billion", "unit": "EUR", "currency": "EUR", "scale": "billion", "value_type": "forecast", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Belén Garijo, Chief Executive Officer", "quote": "My first months as CEO have focused on assessing the challenges facing Sanofi and working on an accelerated transformation roadmap that leverages our commercial strengths and focuses on the need for R&D and pipeline improvements. We have taken the first decisive steps on pipeline prioritisation and recently, we appointed a focused Executive Committee aligned with the strategic priorities. Looking ahead, we're confident in our trajectory of profitable growth: Dupixent sales are now expected to reach around €25 billion in 2030, complemented by approximately €10 billion from Pharma launches — both at constant exchange rates. This strong financial foundation is expected to support continued pipeline enhancement and external growth opportunities in the years ahead. We are committed to acting and reporting on our progress to shareholders and other stakeholders in the quarters to come.", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFK", "bibtex": "@misc{sanofi2026dupixentbjmgfk,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFK},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFB", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFB", "indicator": { "slug": "dupixent-sales-growth", "name": "Dupixent sales growth", "definition": "Percentage growth in sales of Dupixent (dupilumab)." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 37.6, "value_text": "37.6%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Dupixent sales increased by 37.6% to €5.2 billion, above €5 billion per quarter for the first time", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFB", "bibtex": "@misc{sanofi2026dupixentbjmgfb,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFB},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGG0", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGG0", "indicator": { "slug": "free-cash-flow", "name": "Free cash flow", "definition": "Operating cash flow less capital expenditures generated by pharmaceutical and operational activities." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 2670, "value_text": "€2,670m", "unit": "EUR", "currency": "EUR", "scale": "million", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "Free cash flow1          €2,670m         +86.8% —           €3,724m +51.5% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGG0", "bibtex": "@misc{sanofi2026freebjmgg0,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGG0},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGG2", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGG2", "indicator": { "slug": "free-cash-flow", "name": "Free cash flow", "definition": "Operating cash flow less capital expenditures generated by pharmaceutical and operational activities." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 3724, "value_text": "€3,724m", "unit": "EUR", "currency": "EUR", "scale": "million", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "Free cash flow1          €2,670m         +86.8% —           €3,724m +51.5% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGG2", "bibtex": "@misc{sanofi2026freebjmgg2,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGG2},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_SX1A9KYEMQDSD4Y4WJXHMCNAMK", "url": "https://statorigin.org/stat/stat_SX1A9KYEMQDSD4Y4WJXHMCNAMK", "indicator": { "slug": "free-cash-flow-half-year", "name": "Free cash flow (half year)", "definition": "Net operating cash flow minus capital expenditures." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 3724, "value_text": "€3,724m", "unit": "EUR", "currency": "EUR", "scale": "million", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "Free cash flow1 €2,670m +86.8% — €3,724m +51.5% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_SX1A9KYEMQDSD4Y4WJXHMCNAMK", "bibtex": "@misc{sanofi2026freemcnamk,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_SX1A9KYEMQDSD4Y4WJXHMCNAMK},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGG1", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGG1", "indicator": { "slug": "free-cash-flow-growth", "name": "Free cash flow growth", "definition": "Percentage change in free cash flow generated relative to the prior-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 86.8, "value_text": "+86.8%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "Free cash flow1          €2,670m         +86.8% —           €3,724m +51.5% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGG1", "bibtex": "@misc{sanofi2026freebjmgg1,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGG1},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGG3", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGG3", "indicator": { "slug": "free-cash-flow-growth", "name": "Free cash flow growth", "definition": "Percentage change in free cash flow generated relative to the prior-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 51.5, "value_text": "+51.5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "Free cash flow1          €2,670m         +86.8% —           €3,724m +51.5% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGG3", "bibtex": "@misc{sanofi2026freebjmgg3,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGG3},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_06KZ4J7C78PNWWGXHV6DDW8Y46", "url": "https://statorigin.org/stat/stat_06KZ4J7C78PNWWGXHV6DDW8Y46", "indicator": { "slug": "free-cash-flow-growth-half-year", "name": "Free cash flow growth (half year)", "definition": "Percentage change in free cash flow relative to the prior period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 51.5, "value_text": "+51.5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "Free cash flow1 €2,670m +86.8% — €3,724m +51.5% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_06KZ4J7C78PNWWGXHV6DDW8Y46", "bibtex": "@misc{sanofi2026freedw8y46,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_06KZ4J7C78PNWWGXHV6DDW8Y46},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFH", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFH", "indicator": { "slug": "ifrs-earnings-per-share", "name": "IFRS earnings per share", "definition": "Diluted or basic earnings per share reported under International Financial Reporting Standards." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 0.29, "value_text": "€0.29", "unit": "EUR", "currency": "EUR", "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Business EPS was €2.09, up by 33.3% at CER; 31.4% at actual exchange rates; IFRS EPS €0.29", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFH", "bibtex": "@misc{sanofi2026ifrsbjmgfh,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFH},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFY", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFY", "indicator": { "slug": "ifrs-earnings-per-share", "name": "IFRS earnings per share", "definition": "Diluted or basic earnings per share reported under International Financial Reporting Standards." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 1.63, "value_text": "€1.63", "unit": "EUR", "currency": "EUR", "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "IFRS EPS €0.29 -91.0% —            €1.63   -65.6% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFY", "bibtex": "@misc{sanofi2026ifrsbjmgfy,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFY},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_QS2K0P6781VK7CZVXZSPB4YTD3", "url": "https://statorigin.org/stat/stat_QS2K0P6781VK7CZVXZSPB4YTD3", "indicator": { "slug": "ifrs-earnings-per-share-half-year", "name": "IFRS earnings per share (half year)", "definition": "Earnings per share calculated under International Financial Reporting Standards." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 1.63, "value_text": "€1.63", "unit": "EUR", "currency": "EUR", "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "IFRS EPS €0.29 -91.0% — €1.63 -65.6% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_QS2K0P6781VK7CZVXZSPB4YTD3", "bibtex": "@misc{sanofi2026ifrsb4ytd3,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_QS2K0P6781VK7CZVXZSPB4YTD3},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFX", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFX", "indicator": { "slug": "ifrs-earnings-per-share-growth", "name": "IFRS earnings per share growth", "definition": "Percentage change in IFRS earnings per share compared to the prior-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": -91, "value_text": "-91.0%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "IFRS EPS €0.29 -91.0% —            €1.63   -65.6% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFX", "bibtex": "@misc{sanofi2026ifrsbjmgfx,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFX},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFZ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFZ", "indicator": { "slug": "ifrs-earnings-per-share-growth", "name": "IFRS earnings per share growth", "definition": "Percentage change in IFRS earnings per share compared to the prior-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -65.6, "value_text": "-65.6%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "IFRS EPS €0.29 -91.0% —            €1.63   -65.6% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFZ", "bibtex": "@misc{sanofi2026ifrsbjmgfz,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFZ},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_HYEAQQMJ4PTBCHHRV4V1551XGZ", "url": "https://statorigin.org/stat/stat_HYEAQQMJ4PTBCHHRV4V1551XGZ", "indicator": { "slug": "ifrs-earnings-per-share-growth-half-year", "name": "IFRS earnings per share growth (half year)", "definition": "Percentage change in IFRS earnings per share compared to the prior year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": -65.6, "value_text": "-65.6%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "IFRS EPS €0.29 -91.0% — €1.63 -65.6% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_HYEAQQMJ4PTBCHHRV4V1551XGZ", "bibtex": "@misc{sanofi2026ifrs551xgz,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HYEAQQMJ4PTBCHHRV4V1551XGZ},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFS", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFS", "indicator": { "slug": "ifrs-net-income", "name": "IFRS net income", "definition": "Net profit or loss for the period attributable to equity holders under International Financial Reporting Standards." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 343, "value_text": "€343m", "unit": "EUR", "currency": "EUR", "scale": "million", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "IFRS net income €343m -91.3% —           €1,957m -66.3% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFS", "bibtex": "@misc{sanofi2026ifrsbjmgfs,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFS},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFV", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFV", "indicator": { "slug": "ifrs-net-income", "name": "IFRS net income", "definition": "Net profit or loss for the period attributable to equity holders under International Financial Reporting Standards." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": 1957, "value_text": "€1,957m", "unit": "EUR", "currency": "EUR", "scale": "million", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "IFRS net income €343m -91.3% —           €1,957m -66.3% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFV", "bibtex": "@misc{sanofi2026ifrsbjmgfv,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFV},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_7390ME8FES31QJF653RFZ3XV3Q", "url": "https://statorigin.org/stat/stat_7390ME8FES31QJF653RFZ3XV3Q", "indicator": { "slug": "ifrs-net-income-half-year", "name": "IFRS net income (half year)", "definition": "Total net income attributable to equity holders calculated under IFRS standards." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 1957, "value_text": "€1,957m", "unit": "EUR", "currency": "EUR", "scale": "million", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "IFRS net income €343m -91.3% — €1,957m -66.3% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_7390ME8FES31QJF653RFZ3XV3Q", "bibtex": "@misc{sanofi2026ifrsz3xv3q,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7390ME8FES31QJF653RFZ3XV3Q},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFT", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFT", "indicator": { "slug": "ifrs-net-income-growth", "name": "IFRS net income growth", "definition": "Percentage change in IFRS net income compared to the corresponding period of the previous year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": -91.3, "value_text": "-91.3%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "IFRS net income €343m -91.3% —           €1,957m -66.3% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFT", "bibtex": "@misc{sanofi2026ifrsbjmgft,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFT},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFW", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFW", "indicator": { "slug": "ifrs-net-income-growth", "name": "IFRS net income growth", "definition": "Percentage change in IFRS net income compared to the corresponding period of the previous year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "quarter" }, "value": -66.3, "value_text": "-66.3%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "IFRS net income €343m -91.3% —           €1,957m -66.3% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFW", "bibtex": "@misc{sanofi2026ifrsbjmgfw,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFW},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_BNXWYE1SW9J4DC1C3VQCHQVH2V", "url": "https://statorigin.org/stat/stat_BNXWYE1SW9J4DC1C3VQCHQVH2V", "indicator": { "slug": "ifrs-net-income-growth-half-year", "name": "IFRS net income growth (half year)", "definition": "Percentage change in IFRS net income compared to the prior year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": -66.3, "value_text": "-66.3%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026 Change Change at CER H1 2026 Change Change at CER", "quote": "IFRS net income €343m -91.3% — €1,957m -66.3% —", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_BNXWYE1SW9J4DC1C3VQCHQVH2V", "bibtex": "@misc{sanofi2026ifrshqvh2v,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_BNXWYE1SW9J4DC1C3VQCHQVH2V},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFA", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFA", "indicator": { "slug": "pharmaceutical-launches-sales", "name": "Pharmaceutical launches sales", "definition": "Total revenue generated by newly launched pharmaceutical medicines over a given period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 1.3, "value_text": "€1.3 billion", "unit": "EUR", "currency": "EUR", "scale": "billion", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Pharma launches sales increased by 48.3%, reaching €1.3 billion, driven mostly by Ayvakit, ALTUVIIIO, and Sarclisa", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFA", "bibtex": "@misc{sanofi2026pharmaceuticalbjmgfa,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFA},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFM", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFM", "indicator": { "slug": "pharmaceutical-launches-sales-annual", "name": "Pharmaceutical launches sales (annual)", "definition": "Total revenue generated by newly launched pharmaceutical medicines over a given period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2030-01-01", "end": "2030-12-31", "type": "year" }, "value": 10, "value_text": "approximately €10 billion", "unit": "EUR", "currency": "EUR", "scale": "billion", "value_type": "forecast", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Belén Garijo, Chief Executive Officer", "quote": "My first months as CEO have focused on assessing the challenges facing Sanofi and working on an accelerated transformation roadmap that leverages our commercial strengths and focuses on the need for R&D and pipeline improvements. We have taken the first decisive steps on pipeline prioritisation and recently, we appointed a focused Executive Committee aligned with the strategic priorities. Looking ahead, we're confident in our trajectory of profitable growth: Dupixent sales are now expected to reach around €25 billion in 2030, complemented by approximately €10 billion from Pharma launches — both at constant exchange rates. This strong financial foundation is expected to support continued pipeline enhancement and external growth opportunities in the years ahead. We are committed to acting and reporting on our progress to shareholders and other stakeholders in the quarters to come.", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFM", "bibtex": "@misc{sanofi2026pharmaceuticalbjmgfm,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFM},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGF9", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF9", "indicator": { "slug": "pharmaceutical-launches-sales-growth", "name": "Pharmaceutical launches sales growth", "definition": "Percentage increase in sales generated by newly launched pharmaceutical products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 48.3, "value_text": "48.3%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Pharma launches sales increased by 48.3%, reaching €1.3 billion, driven mostly by Ayvakit, ALTUVIIIO, and Sarclisa", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF9", "bibtex": "@misc{sanofi2026pharmaceuticalbjmgf9,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF9},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFF", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFF", "indicator": { "slug": "research-and-development-expenses", "name": "Research and development expenses", "definition": "Total expenditure dedicated to pharmaceutical research and development activities." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 2.2, "value_text": "€2.2 billion", "unit": "EUR", "currency": "EUR", "scale": "billion", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Research and Development expenses reached €2.2 billion, up by 17.9%, including cost from pipeline prioritisations", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFF", "bibtex": "@misc{sanofi2026researchbjmgff,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFF},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_8F3YD9WWDJHMF63N5YG384K8EC", "url": "https://statorigin.org/stat/stat_8F3YD9WWDJHMF63N5YG384K8EC", "indicator": { "slug": "research-and-development-expenses-growth", "name": "Research and development expenses growth", "definition": "Percentage change in research and development expenses compared to the prior year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 17.9, "value_text": "17.9%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Research and Development expenses reached €2.2 billion, up by 17.9%, including cost from pipeline prioritisations", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_8F3YD9WWDJHMF63N5YG384K8EC", "bibtex": "@misc{sanofi2026research84k8ec,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_8F3YD9WWDJHMF63N5YG384K8EC},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGF7", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF7", "indicator": { "slug": "sales-growth-at-constant-exchange-rates", "name": "Sales growth at constant exchange rates", "definition": "Percentage change in sales calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 17.8, "value_text": "17.8%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Q2 sales growth of 17.8% at CER1 and business earnings per share (EPS)2 of €2.09", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF7", "bibtex": "@misc{sanofi2026salesbjmgf7,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGF7},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFJ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFJ", "indicator": { "slug": "sales-growth-at-constant-exchange-rates-annual", "name": "Sales growth at constant exchange rates (annual)", "definition": "Percentage change in sales calculated at constant exchange rates over the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-12-31", "type": "year" }, "value": 10, "value_text": "around 10%", "unit": "percent", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Guidance upgraded", "quote": "In 2026, sales are now expected to grow by around 10% at CER.", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFJ", "bibtex": "@misc{sanofi2026salesbjmgfj,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFJ},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_M1K7KZBDE9Y6SBE3E5PCY586XK", "url": "https://statorigin.org/stat/stat_M1K7KZBDE9Y6SBE3E5PCY586XK", "indicator": { "slug": "selling-and-general-expenses", "name": "Selling and general expenses", "definition": "Total expenditure related to selling, general, and administrative operations." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 2.5, "value_text": "€2.5 billion", "unit": "EUR", "currency": "EUR", "scale": "billion", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Selling and general expenses reached €2.5 billion, up by 9.0%, mainly because of recent acquisitions and one-offs", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_M1K7KZBDE9Y6SBE3E5PCY586XK", "bibtex": "@misc{sanofi2026sellingy586xk,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_M1K7KZBDE9Y6SBE3E5PCY586XK},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_A6HF0BBWACAQPH14RXA4X2P01M", "url": "https://statorigin.org/stat/stat_A6HF0BBWACAQPH14RXA4X2P01M", "indicator": { "slug": "selling-and-general-expenses-growth", "name": "Selling and general expenses growth", "definition": "Percentage increase in selling and general expenses relative to the prior period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 9, "value_text": "9.0%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Selling and general expenses reached €2.5 billion, up by 9.0%, mainly because of recent acquisitions and one-offs", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_A6HF0BBWACAQPH14RXA4X2P01M", "bibtex": "@misc{sanofi2026sellingx2p01m,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_A6HF0BBWACAQPH14RXA4X2P01M},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFE", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFE", "indicator": { "slug": "vaccines-sales", "name": "Vaccines sales", "definition": "Total net sales revenue generated from vaccine products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 1.1, "value_text": "€1.1 billion", "unit": "EUR", "currency": "EUR", "scale": "billion", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Vaccines sales decreased by 4.7% to €1.1 billion, impacted by a high basis of comparison in influenza vaccines", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFE", "bibtex": "@misc{sanofi2026vaccinesbjmgfe,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFE},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGFD", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFD", "indicator": { "slug": "vaccines-sales-growth", "name": "Vaccines sales growth", "definition": "Percentage growth rate of sales within the vaccine product portfolio." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": -4.7, "value_text": "4.7%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Sanofi", "org_short_name": "Sanofi", "org_url": "https://www.sanofi.com", "org_tier": 2, "document_title": "Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "document_url": "https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767", "document_type": "press_release", "locator": "Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded", "quote": "Vaccines sales decreased by 4.7% to €1.1 billion, impacted by a high basis of comparison in influenza vaccines", "published_date": "2026-07-30", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Sanofi. (2026). Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded. Retrieved September 15, 2026, from https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFD", "bibtex": "@misc{sanofi2026vaccinesbjmgfd,\n author = {{Sanofi}},\n title = {Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGFD},\n note = {Original source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-07-30-05-30-00-3335767. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" } ] }, "meta": { "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.", "license": "https://creativecommons.org/licenses/by/4.0/", "docs": "https://statorigin.org/docs/api", "total": 40, "note": "Statistics are capped at 100 per request. Use /statistics?source_org=sanofi with a cursor to page through everything." } }